Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains
AssigneeIntervet International B.V.
InventorsEgbert Mundt, Tobias Letzel, Guntram Paul, Adriaan Antonius Wilhelmus Maria van Loon
Life of this patent
Estimating the term…
Abstract
The present invention provides a classic IBDV mutant that additionally comprises virus neutralising epitopes 67 (specific for variant-E IBDV).
Claims16
A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
- (i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and
- (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at positions 318-323.
A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HE-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
- (i) a codon for the amino acid at position 222 encoding threonine, and
- (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID. No. 4, and SEQ ID No. 5 at positions 318-323.
Dependencies are inferred from the claim text.